Draig Therapeutics

Draig Therapeutics, Ltd. is a developer of a biotechnology platform aimed at providing effective treatments for neuropsychiatric disorders. The company's platform focuses on developing first-in-class modulators of the major excitatory and inhibitory neurotransmitters, glutamate and GABA, to restore synaptic balance and deliver transformative therapeutic benefits, enabling patients with inhibitory neurotransmitter issues to receive effective treatment.